l dopa decarboxylase/dyskinesias

Nuoroda įrašoma į mainų sritį

StraipsniaiKlinikiniai tyrimaiPatentai

Pasirinkite rūšiavimo tipą

7 rezultatus

[Bromocriptin in the treatment of progressive stages of Parkinson's disease (author's transl)].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Forty patients with severe Parkinson's disease (23 men, 17 women) who had been treated for six years with L-dopa-decarboxylase inhibitor, were part of a placebo-controlled double-blind trial to test the effectiveness of bromocriptin. In all patients the effectiveness of L-dopa had been decreasing,

Routine outpatient L-dopa monitoring in elderly patients with Parkinson's disease.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

In an attempt to improve the therapeutic drug management of patients with Parkinson's disease, plasma L-dopa concentrations were measured by high-performance liquid chromatography and related to the post-dose time with reference to an established therapeutic range of 0.3-1.6 mg/l. The response to

[Juvenile Parkinson's disease initially presenting as bulbar incoordination: a case report].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

We report a case of juvenile Parkinson's disease which initially presented as bulbar incoordination at the age 12. The condition was characterized by dystonia of the upper extremities. The patient was a 14-year-old female. The patient's main symptoms were bulbar dysfunction. Resting and action

Optimum symptomatic control of Parkinson's disease with dopaminergic therapy.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

This paper presents a review of the literature on the therapeutic action and the side effects of the two main dopaminergic agents: L-DOPA/decarboxylase inhibitor (L-DOPA/DI) and bromocriptine (Parlodel used either as monotherapy or in combination in patients with Parkinson's disease. The combination

[Trazodone in involuntary pathologic movements].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The authors report an experiment undertaken with trazodone in the treatment of different forms of pathological involuntary movements. Forty-five subjects were treated for two months; 15 were affected with L-DOPA + decarboxylase inhibitor induced dyskinesias, 9 with choreic or choreoathetosic

[Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

In a 59-year-old male with a 10 year history of Parkinson's disease, progressive movement disorders occurred under medical treatment (end-of-dose akinesia and peak-dose dyskinesia). Thereupon his treatment was changed to a combination of L-dopa/ decarboxylase inhibitor administered during the day in

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Ten-year follow-up results from the Parkinson's Disease Research Group of the United Kingdom trial demonstrated that there were no long-term advantages to initiating treatment with bromocriptine compared with l-dopa in early Parkinson disease (PD). Increased mortality in patients on

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais